Edition:
United States

OvaScience Inc (OVAS.OQ)

OVAS.OQ on NASDAQ Stock Exchange Capital Market

0.69USD
7 Dec 2018
Change (% chg)

$-0.05 (-6.85%)
Prev Close
$0.74
Open
$0.73
Day's High
$0.77
Day's Low
$0.69
Volume
27,318
Avg. Vol
--
52-wk High
$1.51
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Millendo Therapeutics Says Selling Stockholders Of Co May Offer And Resell Up To 1.2 Mln Shares Of Co's Common Stock Under Prospectus
Thursday, 20 Dec 2018 04:46pm EST 

Dec 20 (Reuters) - Millendo Therapeutics Inc ::MILLENDO THERAPEUTICS INC SAYS SELLING STOCKHOLDERS OF CO MAY OFFER AND RESELL UP TO 1.2 MILLION SHARES OF CO'S COMMON STOCK UNDER PROSPECTUS -SEC FILING.  Full Article

Ovascience And Millendo Therapeutics Provide Update On Merger Agreement And Financing
Thursday, 1 Nov 2018 04:01pm EDT 

OvaScience Inc ::OVASCIENCE AND MILLENDO THERAPEUTICS PROVIDE UPDATE ON MERGER AGREEMENT AND FINANCING.OVASCIENCE INC - NEW COMMITMENT BY GREAT POINT PARTNERS BRINGS PROCEEDS OF TRANSACTIONS TO $87 MILLION.OVASCIENCE INC - TOTAL PROCEEDS OF MERGER AND FINANCING ARE EXPECTED TO BE APPROXIMATELY $87 MILLION.OVASCIENCE INC - UPDATED TERMS OF THEIR MERGER AGREEMENT AND INCREASED SIZE OF ASSOCIATED FINANCING.OVASCIENCE INC - PROCEEDS WILL FUND FURTHER DEVELOPMENT OF MILLENDO'S LEAD ASSETS, LIVOLETIDE AND NEVANIMIBE.OVASCIENCE INC - FINANCING AND MERGER ARE EXPECTED TO CLOSE IN Q4 OF 2018.OVASCIENCE INC - INVESTORS PARTICIPATING IN FINANCING WILL ACQUIRE APPROXIMATELY 20% OF COMBINED COMPANY.OVASCIENCE INC - ESTIMATED EXCHANGE RATIO IN MERGER AGREEMENT HAS BEEN REVISED.OVASCIENCE INC - ON A PRO FORMA BASIS, CURRENT OVASCIENCE SECURITYHOLDERS WILL OWN APPROXIMATELY 17% OF COMBINED COMPANY.OVASCIENCE INC - CURRENT MILLENDO SECURITYHOLDERS (ASSUMING MILLENDO OPTION POOL IS FULLY ALLOCATED) WILL OWN APPROXIMATELY 63% OF COMBINED CO.OVASCIENCE - WITH ADDITIONAL INVESTMENT, SECURITYHOLDERS TO HAVE GREATER OWNERSHIP OF COMBINED CO- NOW WITH POST-MONEY VALUATION OF ABOUT $246 MILLION.  Full Article

Prosight Management Lp Reports 5.6 Percent Passive Stake In Ovascience Inc As Of October 16
Friday, 26 Oct 2018 03:04pm EDT 

Oct 26 (Reuters) - :PROSIGHT MANAGEMENT LP REPORTS 5.6 PERCENT PASSIVE STAKE IN OVASCIENCE INC AS OF OCTOBER 16 - SEC FILING.  Full Article

Ovascience Reports Q2 Loss Per Share Of $0.22
Thursday, 9 Aug 2018 04:01pm EDT 

Aug 9 (Reuters) - OvaScience Inc ::OVASCIENCE REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC ALTERNATIVES UPDATE.Q2 LOSS PER SHARE $0.22.AS OF JUNE 30, 2018, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $53.6 MILLION.RESTRUCTURING EXPENSES FOR QUARTER ENDED JUNE 30, 2018 WERE $2.9 MILLION.AN INVESTOR SYNDICATE HAS COMMITTED TO INVEST $30 MILLION IN COMBINED COMPANY.  Full Article

BML Investment Partners Reports 6.4 Pct Passive Stake In Ovascience
Wednesday, 28 Mar 2018 04:17pm EDT 

March 28 (Reuters) - Ovascience Inc ::BML INVESTMENT PARTNERS LP REPORTS 6.4 PERCENT PASSIVE STAKE IN OVASCIENCE INC AS OF MARCH 28 - SEC FILING.  Full Article

Ovascience Reports Q4 Loss Per Share $0.24
Thursday, 15 Mar 2018 04:01pm EDT 

March 15 (Reuters) - Ovascience Inc ::OVASCIENCE REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.24.Q4 EARNINGS PER SHARE VIEW $-0.28 -- THOMSON REUTERS I/B/E/S.EXPECTS TO INCUR ADDITIONAL CASH OUTLAYS RELATED TO RESTRUCTURINGS OF BETWEEN $1.0 MILLION AND $1.5 MILLION OVER 2018.ANTICIPATES THAT IT WILL HAVE SUFFICIENT FUNDS WITHOUT ADDITIONAL FINANCING TO SUPPORT ITS OPERATIONS INTO 2020.  Full Article

OvaScience Says Provided Intrexon Corp With Written Notice Of Termination Of Exclusive Channel Collaboration Agreement, Dated Dec 18, 2013
Thursday, 1 Feb 2018 05:18pm EST 

Feb 1 (Reuters) - OvaScience Inc ::OVASCIENCE SAYS PROVIDED INTREXON CORP WITH WRITTEN NOTICE OF TERMINATION OF EXCLUSIVE CHANNEL COLLABORATION AGREEMENT, DATED DEC 18, 2013-SEC FILING.OVASCIENCE INC - PURSUANT TO TERMS OF OVATURE ECC, TERMINATION IS EFFECTIVE 90 DAYS FOLLOWING NOTICE.OVASCIENCE INC - "DO NOT EXPECT THE TERMINATION OF THE OVATURE ECC TO HAVE A MATERIAL IMPACT ON OUR PROGRESS".  Full Article

Ovascience Says ‍Reducing Headcount By Approximately 50 Percent​
Wednesday, 3 Jan 2018 04:06pm EST 

Jan 3 (Reuters) - Ovascience Inc ::OVASCIENCESM ANNOUNCES CORPORATE UPDATE.OVASCIENCE INC - ‍REDUCING HEADCOUNT BY APPROXIMATELY 50 PERCENT​.OVASCIENCE INC - ‍MAJORITY OF REDUCTION IN PERSONNEL IS EXPECTED TO BE COMPLETED BY MARCH 2018​.OVASCIENCE INC - JAMES LILLIE JOINING AS CHIEF SCIENTIFIC OFFICER.OVASCIENCE INC - ‍AS A RESULT OF REDUCTION IN PERSONNEL, CO EXPECTS TO REALIZE ANNUALIZED COST SAVINGS BEGINNING IN Q2 OF 2018​.OVASCIENCE INC - ‍ESTIMATES THAT IT WILL INCUR ONE-TIME COSTS OF APPROXIMATELY $1.0 MILLION TO $1.5 MILLION RELATED TO RESTRUCTURING PLAN​.OVASCIENCE INC - ‍PLANS TO INITIATE A MULTI-CENTER, PROSPECTIVE, CONTROLLED, PHASE 1B/2A CLINICAL TRIAL OF OVAPRIME​.OVASCIENCE INC - ‍EXPECTS TO BEGIN PATIENT ENROLLMENT IN FIRST HALF OF 2018 AND TO REPORT INITIAL CLINICAL DATA IN 2019​ FROM PLANNED OVAPRIME TRIAL.  Full Article

Ovascience reports Q3 loss per share $0.26
Thursday, 2 Nov 2017 04:02pm EDT 

Nov 2 (Reuters) - Ovascience Inc :Ovascience reports third quarter 2017 financial results.Q3 loss per share $0.26.Q3 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Ovascience Inc - ‍expects to incur additional cash outlays related to restructurings of between $1.0 million and $1.5 million over 2017 and 2018​.Ovascience Inc - ‍anticipates that it will have sufficient funds without additional financing to support its operations into q1 of 2020​.  Full Article

Ovascience Q2 loss per share $0.51
Thursday, 3 Aug 2017 04:02pm EDT 

Aug 3 (Reuters) - Ovascience Inc :Ovascience reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Ovascience Inc - ‍as of June 30, 2017, Ovascience had cash, cash equivalents and short-term investments of $86.6 million​.Ovascience Inc - ‍expect total one-time cash expenditures resulting from two restructurings to be between $8 and $9 million over 2017 and 2018​.Ovascience Inc - ‍anticipates that it will have sufficient funds, without additional financing, to support its operating plan into Q1 of 2020​.  Full Article